Lung Cancer

Avelumab (Bavencio) missed the primary endpoint of improving overall survival in pretreated patients with non–small cell lung cancer, according to findings from the phase III JAVELIN Lung 200 Trial.

Sagus Sampath, MD, assistant professor, Department of Radiation Oncology, City of Hope, discusses the safety profile of immunotherapy in combination with radiation in the treatment of patients with lung cancer.

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses combination regimens for patients with EGFR-positive non-small cell lung cancer (NCSLC).

ALK inhibitors have followed a rapid trajectory from bench to bedside, taking over from chemotherapy as standard frontline treatment for patients with advanced non– small-cell lung cancer with ALK gene rearrangements.

A recent study of oncologists’ use of next-generation sequencing to test for actionable genetic mutations reveals a stark gap between the appropriateness and the actual utilization of these tests.

The FDA has granted a priority review to a new drug application for lorlatinib for use in patients with ALK-positive metastatic non–small cell lung cancer who have progressed on 1 or more ALK TKIs.

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses pembrolizumab (Keytruda) in non-small cell lung cancer.

Thomas Eldridge Stinchcombe, MD, recaps recent data with immunotherapy as a single agent and in combination in NSCLC and what challenges the field is facing in 2018.

Thomas E. Stinchcombe, MD, professor of medicine, Duke Cancer Institute, discusses the PACIFIC trial for patients with non–small cell lung cancer (NSCLC).

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses the factors that contribute to disparities in the treatment of patients with lung cancer.

The combination of nivolumab and ipilimumab improved progression-free survival compared with chemotherapy in treatment-naïve patients with high tumor mutation burden non–small cell lung cancer.

Ravi Salgia, MD, PhD, Arthur & Rosalie Kaplan Chair in Medical Oncology, associate director for clinical sciences at City of Hope, discusses the importance of molecular markers in lung cancer.

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses the tolerability of a new third-generation T790-specific inhibitor, osimertinib (Tagrisso).

Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).